Gabather
0,7 SEK -5,41%1 investor følger denne virksomhed
Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
GABA
Daglig lav / høj pris
0,7 / 0,702
SEK
Markedsværdi
26,44 mio. SEK
Aktieomsætning
11,49 t SEK
Volumen
16 t
Finanskalender
Delårsrapport
29.08.2024
Delårsrapport
28.11.2024
Årsrapport
27.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Avanza Pension | 14,4 % | 14,4 % |
Investment Aktiebolaget Balticum | 2,4 % | 2,4 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools